Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

Open Compound Sourcing

Explore the therapeutic potential of your compounds with us

Through our Open Compound Sourcing initiative, we invite potential partners to submit their compounds to be included in our high throughput screening library and utilized in efforts to identify new therapeutics.

We are looking for novel small organic chemical compounds for testing in our screening campaigns for potential therapeutic activity. Many of these compounds might otherwise never be tested for potential therapeutic benefits. In case of a match, specific compounds could become the next new chemical entity (NCE) or starting point for further optimization in one of our strategic therapeutic areas of focus: Oncology, Neurodegenerative Diseases and Rheumatology.

This program is not open to U.S. healthcare professionals.

We invite universities, research institutes and private companies to sign a “Participation and Material Supply Agreement (P&MSA)”. The agreement will cover the legal, intellectual property and commercial aspects of transferring your novel small organic compounds to Merck KGaA, Darmstadt, Germany.

Register to participate in the Open Compound Sourcing Initiative. After registration, you will have access to the P&MSA.

Downloads (login required)

To be tested for potential pharmaceutical activity, compounds must have the following property profile:

  • Small organic compound with molecular weight between 150 and 450
  • No inorganic elements (except usual counter ions)
  • Not part of publicly available databases or vendor catalogues
  • Symmetry < C2v
  • A minimum of three N or O atoms
  • Less than 50% of heavy atoms being N or O
  • Log of calculated solubility in water at pH 7.4 in mol/l (LogS74 mol/l) > -6
  • Obeying Lipinski's Rule-of-Five (max one violation of the following conditions: Molecular weight ≤ 500, LogP ≤ 5, number of H-bond acceptors ≤ 10, number of H-bond donors ≤ 5. For a reference see here)
  • No pharmacologically undesirable substructures contained (not disclosed here)
Compounds must also meet the following criteria:

  • Crystalline powder (oils will not be accepted)
  • Purity should be equal to or exceeding 90 %
  • No cooling required
  • No mixtures
  • No biologicals, no natural compounds, no extracts
  • No known toxicity
  • No radioactive compounds
The first step is to tell us about your compound. Qualified participants (see “Who can apply”) should electronically submit proposed structures using the link on this web page.

We will then review your application and confirm by email if any compounds are of interest to us. At that point, we will facilitate shipment of compounds to us for final analysis.

Download full details on submission process (login required)

For each compound accepted for inclusion in our Screening Library, the partner will receive EUR 200 for exclusive compounds, and EUR 100 for non-exclusive compounds.

If a compound qualifies as a hit during our screening campaigns, the partner will be further compensated according to the terms of the P&MSA. We will then contact you to explore how best to advance this opportunity together.

By participating in our Open Compound Sourcing, your novel small molecule could become a much-needed therapy helping transform the lives of patients with serious unmet medical needs or a promising starting point for further chemical optimization to achieve that goal.



Please send inquiries to us by e-mail
Submit your proposal

Open Source